Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) is a X-linked rare disorder that generally occurs in males. Adrenoleukodystrophy commonly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. As a X-linked disorder, Adrenoleukodystrophy presents is mostly found in males and occurs in about one out of every 17,000 births. Approximately two-thirds of Adrenoleukodystrophy patients suffer from childhood cerebral form of the disease, the most severe form of the disease. It is characterized by normal development in early childhood, followed by rapid degeneration to a vegetative state. The drug candidates of Adrenoleukodystrophy pipeline include, but are not limited to, MIN-102, VK0214 and MD1003. Some of the companies having drugs for Adrenoleukodystrophy in pipeline are Minoryx Therapeutics S.L., Viking Therapeutics Inc., MedDay SA, and bluebird bio Inc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.